Immunomodulation in cancer

Current Opinion in Pharmacology

Volumn 17, Issue 1, 2014, Pages 17-21

  Hegmans, Joost P J J ^a   Aerts, Joachim G J V ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; GALECTIN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 35; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 LIGAND 1; SIPULEUCEL T; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELL VACCINE; CANCER VACCINE; IMMUNOLOGIC FACTOR; TUMOR MARKER;

ADOPTIVE IMMUNOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL INTERACTION; CELLULAR IMMUNITY; CYTOKINE RELEASE; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; MEDICAL DECISION MAKING; MEMORY T LYMPHOCYTE; MOLECULAR DYNAMICS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TUMOR CELL; TUMOR IMMUNOLOGY; TUMOR MICROENVIRONMENT; ANIMAL; DRUG DESIGN; DRUG EFFECTS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE;

ANIMALS; CANCER VACCINES; DRUG DESIGN; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; LYMPHOCYTES, TUMOR-INFILTRATING; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84904804626     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.06.007     Document Type: Review

References (48)

1. J. Couzin-Frankel Breakthrough of the year 2013. Cancer immunotherapy Science 342 2013 1432 1433
2. M.A. Cheever, and C.S. Higano PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine Clin Cancer Res 17 2011 3520 3526
3. F.S. Hodi et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
4. K. Traynor Ipilimumab approved for metastatic melanoma Am J Health Syst Pharm 68 2011 768
5. P.J. Campbell et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer Nature 467 2010 1109 1113
6. M. Gerlinger et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N Engl J Med 366 2012 883 892
7. A. Sottoriva et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics Proc Natl Acad Sci U S A 110 2013 4009 4014
8. D. Hanahan, and L.M. Coussens Accessories to the crime: functions of cells recruited to the tumor microenvironment Cancer Cell 21 2012 309 322
9. J.P. Vayrynen et al. Detailed analysis of inflammatory cell infiltration in colorectal cancer Br J Cancer 109 2013 1839 1847
10. M.E. Heuvers et al. Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment BMC Cancer 12 2012 580
11. L.A. Lievense et al. Tumor-associated macrophages in thoracic malignancies Lung Cancer 80 2013 256 262
12. D.F. Quail, and J.A. Joyce Microenvironmental regulation of tumor progression and metastasis Nat Med 19 2013 1423 1437
13. W.H. Fridman et al. The immune microenvironment of human tumors: general significance and clinical impact Cancer Microenviron 6 2013 117 122
14. N.A. Giraldo et al. The immune contexture of primary and metastatic human tumours Curr Opin Immunol 27C 2014 8 15
15. W.H. Fridman et al. The immune contexture in human tumours: impact on clinical outcome Nat Rev Cancer 12 2012 298 306
16. H. Angell, and J. Galon From the immune contexture to the 'Immunoscore': the role of prognostic and predictive immune markers in cancer Curr Opin Immunol 25 2013 261 267
17. J. Galon et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours J Pathol 232 2014 199 209
18. J. Galon et al. Cancer classification using the Immunoscore: a worldwide task force J Transl Med 10 2012 205
19. J.P. Hegmans, and J.G. Aerts Immunological profiling as a means to invigorate personalized cancer therapy Oncoimmunology 2 2013 e25236
20. L. De Mattos-Arruda, and J. Rodon Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection Oncologist 18 2013 1180 1188
21. L. Galluzzi et al. Trial watch: monoclonal antibodies in cancer therapy Oncoimmunology 1 2012 28 37
22. A. Bailey, and D.F. McDermott Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics Cancer J 19 2013 348 352
23. S. Champiat et al. Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC J Thorac Oncol 9 2014 144 153
24. F. Aranda et al. Trial watch: peptide vaccines in cancer therapy Oncoimmunology 2 2013 e26621
25. L. Senovilla et al. Trial watch: DNA vaccines for cancer therapy Oncoimmunology 2 2013 e23803
26. E. Vacchelli et al. Trial watch: oncolytic viruses for cancer therapy Oncoimmunology 2 2013 e24612
27. E. Vacchelli et al. Trial watch: peptide vaccines in cancer therapy Oncoimmunology 1 2012 1557 1576
28. P. Gould Sipuleucel-T shows partial advantage in prostate cancer Lancet Oncol 7 2006 710
29. P.W. Kantoff et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 2010 411 422
30. J.P. Hegmans et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma Am J Respir Crit Care Med 181 2010 1383 1390
31. C.S. Hinrichs, and S.A. Rosenberg Exploiting the curative potential of adoptive T-cell therapy for cancer Immunol Rev 257 2014 56 71
32. E. Ames, and W.J. Murphy Advantages and clinical applications of natural killer cells in cancer immunotherapy Cancer Immunol Immunother 63 2014 21 28
33. E. Vacchelli et al. Trial watch: adoptive cell transfer for anticancer immunotherapy Oncoimmunology 2 2013 e24238
34. L.A. Lievense, J.P. Hegmans, and J.G. Aerts Biomarkers for immune checkpoint inhibitors Lancet Oncol 15 2014 e1
35. P.A. Ascierto et al. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment J Transl Med 11 2013 54
36. M. Holzel, A. Bovier, and T. Tuting Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer 13 2013 365 376
37. D.I. Gabrilovich, S. Ostrand-Rosenberg, and V. Bronte Coordinated regulation of myeloid cells by tumours Nat Rev Immunol 12 2012 253 268
38. J. Galon et al. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures Immunity 39 2013 11 26
39. G. Bindea et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer Immunity 39 2013 782 795
40. L. Zitvogel, and G. Kroemer Targeting PD-1/PD-L1 interactions for cancer immunotherapy Oncoimmunology 1 2012 1223 1225
41. O.M. Grauer et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo Int J Cancer 121 2007 95 105 (Pubitemid 46753856)
42. L.S. Shen et al. CD4(+)CD25(+)CD127(low/-) regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression Clin Immunol 131 2009 109 118
43. S. Yaqub et al. Regulatory T cells in colorectal cancer patients suppress anti-tumor immune activity in a COX-2 dependent manner Cancer Immunol Immunother 57 2008 813 821 (Pubitemid 351660125)
44. R. Ramakrishnan, and D.I. Gabrilovich Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer Cancer Immunol Immunother 62 2013 405 410
45. G. Kroemer et al. Immunogenic cell death in cancer therapy Annu Rev Immunol 31 2013 51 72
46. F. Palombo, C. Focaccetti, and V. Barnaba Therapeutic implications of immunogenic cell death in human cancer Front Immunol 4 2014 503
47. B.F. Judy, and S. Singhal How can cytoreduction surgery improve the prospects for cancer patients receiving immunotherapy? Immunotherapy 4 2012 1077 1080
48. S.K. Seung et al. Radiation and immunotherapy: renewed allies in the war on cancer Oncoimmunology 1 2012 1645 1647